metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population
versus irinotecan, paclitaxel
	avelumab alone
	JAVELIN Gastric 300, 2018 Ann. Oncol. 2018; 29:2052-2060 NCT02625623	RCT	mGC or mGEJC - L2 - all population	avelumab	physician's choice of chemotherapy (paclitaxel or irinotecan)	patients with unresectable, recurrent, locally advanced, or metastatic gastric cancer/gastro-oesophageal junction cancer with disease progression after second-line treatment	185 / 186	some concern	inconclusive	inconclusive 10 % increase in deaths (OS) (PE) statistically significant 73 % increase in progression or deaths (PFS) statistically significant 63 % decrease in DCR
versus paclitaxel
	pembrolizumab alone
	KEYNOTE-061 (all population), 2018 Lancet 2018; 392:123-133 NCT02370498	RCT	mGC or mGEJC - L2 - all population	pembrolizumab	paclitaxel	patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine	296 / 296	some concern	inconclusive	statistically significant 49 % increase in progression or deaths (PFS)
versus placebo
	nivolumab alone
	ATTRACTION-2 (Kang), 2017 Gastric Cancer 2019; 22:344-354 Gastric Cancer 2020; 23:143-153 Gastric Cancer 2021 Mar 20. Lancet 2017; 390:2461-2471 NCT02267343	RCT	mGC or mGEJC - L2 - all population	nivolumab	placebo	patients with advanced gastric or gastro-oesophageal junction cancer who had been previously been treated with two or more chemotherapy regimens	330 / 163	low	inconclusive	suggested 37 % decrease in deaths (OS) (PE) suggested 38 % decrease in deaths (OS) (extension) suggested 40 % decrease in PFS (extension) suggested 40 % decrease in progression or deaths (PFS)
versus Standard of Care (SoC)
	Ipilimumab (10 mg/kg)
	CA184-162, 2017 Clin. Cancer Res. 2017; 23:5671-5678 NCT01585987	RCT	mGC or mGEJC - L2 - all population	ipilimumab	SoC (maintenance)	patients with unresectable locally advanced/ metastatic gastric or gastroesophageal junction (GEJ) cancer who achieved at least stable disease (SD) following first-line treatment with combination platinum-fluoropyrimidine chemotherapy	57 / 57	some concern	inconclusive	statistically significant 59 % increase in progression or deaths (PFS) statistically significant 44 % increase in irPFS (PE)
mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive
versus paclitaxel
	pembrolizumab alone
	KEYNOTE-061 (PDL1 CPS>1), 2018 Lancet 2018; 392:123-133 Gastric Cancer 2022; 25:197-206-. NCT02370498	RCT	mGC or mGEJC - L2 - PDL1 positive	pembrolizumab	paclitaxel	patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine (PDL1 CPS>1 population)	196 / 199	some concern	inconclusive	inconclusive 18 % decrease in deaths (OS) (PE) statistically significant 27 % increase in progression or deaths (PFS) (PE)

mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population

mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive